UTVECKLING AV BIOLOGISKT LÄKEMEDEL FÖR ORALA INDIKATIONERNA PERIODONTIT OCH PERI-IMPLANTIT
Diarienummer | |
Koordinator | Omnio AB |
Bidrag från Vinnova | 3 000 000 kronor |
Projektets löptid | juni 2019 - oktober 2021 |
Status | Avslutat |
Utlysning | Swelife och Medtech4Health - samverkansprojekt för bättre hälsa |
Syfte och mål
The aim was to develop two plasminogen-based drug candidates for treatment of periodontitis and peri-implantitis. The goal was to have an injectable and a paste/ointment/granule for topical application. The work with injectable plasminogen for treatment of periodontitis has progressed well using our mouse models. For topical treatment we have identified that a carrier substance (Lyostypt) which is already used in oral indications can adsorb plasminogen and thus be used as a carrier material. The work on peri-implantitis was technically very difficult but is still on-going.
Resultat och förväntade effekter
We have discussed with experts to evaluate and select a proper treatment strategy as well as the regulatory requirements. Since our industrial partner sold the plasminogen production capacity we decided to produce recombinant GMP-plasminogen on our own. Funding for this was obtained through a private placement and a CMO has been selected. A letter of intent for the financing of the project through clinical trials have been obtained. The periodontitis and peri-implantitis models in rodents have been optimized. Formulation studies for topical formulations have been performed.
Upplägg och genomförande
We now have found investors that in three rounds will finance the development of plasminogen to a drug product and finance the first clinical trial. The first investment round that we have obtained are now used to produce GMP-quality recombinant plasminogen. This is on-going. Development of formulations for topical treatment are in progress using our animal models.